9966 — Alphamab Oncology Share News
0.000.00%
Last trade - 00:00- HK$5.54bn
- HK$4.18bn
- CNY566.24m
Brief: Cspc Pharmaceutical Announces Exclusive License Agreement With Jiangsu Alphamab
Brief: Alphamab Oncology Announces Technology Development Collaboration With Suzhou Alphamab
Brief: Alphamab Oncology Says Xu Weihao Appointed As CFO
Brief: Alphamab Oncology Posts FY Loss Of RMB427.8 Mln
Brief: Alphamab Oncology Announces IND Approval For Phase II Clinical Trial Of KN046 In U.S.
HK-listed Alphamab Oncology hits 7-week high on Stock Connect inclusion
Brief: Alphamab Oncology Says INCLUSION OF Co's Shares In Hong Kong Stock Connect List
Brief: Alphamab Oncology Granted Us Fda Orphan Drug Designation To Combination Therapy Of Kn026 And Kn046 Developed By Unit
Brief: Alphamab Oncology Says On Dec 17, NMPA Accepted Biologic License Application For KN035
Brief: Alphamab Oncology Says Engagement Of Shuai Qi Terry As CFO Terminated
Brief: Alphamab Oncology Says Its Combination Therapy Achieved Preliminary Positive Results
Advisory: Dated earnings alerts on Hong Kong-listed companies withdrawn
Brief: Alphamab Oncology Says U.S. FDA Granted Orphan Drug Designation To KN046
Brief: Alphamab Oncology Says HY Loss RMB103.1 Mln
Brief: Alphamab Oncology Says Rubymab To Sell 14.5 Mln Existing Shares Of Co
Brief: Alphamab Oncology Says Unit & Institut Pasteur Of Shanghai Entered Into Cooperative Development Agreement
Brief: Alphamab Oncology Says Strategic Collaboration With Sanofi On Kn026 In Her2+ Breast Cancer
Brief: Alphamab Oncology Says Unit And Sunshine Lake Pharma Co Entered Into Collaboration Agreement
Brief: Alphamab Oncology Says Unit Got U.S. FDA Approval To Proceed With Phase II Clinical Trial Of KN046